HP D300 offers speed and reliability for drug titrations at GSK
3 June 2014 | By kdc communication
GlaxoSmithKline’s quest for improved anti-malarial treatments has been revolutionized by the speed and reliability of the HP D300 Digital Dispenser...
List view / Grid view
News
AstraZeneca’s novel antibiotic candidate AZD0914 given Fast Track status by US FDA
3 June 2014 | By AstraZeneca
AstraZeneca announced that the US Food and Drug Administration has designated its novel investigational drug AZD0914 as a Qualified Infectious Disease Product...
Amgen presents new data on talimogene laherparepvec as single agent and combination therapy in metastatic melanoma at ASCO
3 June 2014 | By Amgen
Amgen announced new data from two key clinical trials that support the potential of talimogene laherparepvec, a novel, investigational oncolytic immunotherapy, as both a single agent and as part of a combination regimen in patients with metastatic melanoma...
AstraZeneca updates on the rapid progress of its oncology pipeline at ASCO 2014
3 June 2014 | By AstraZeneca
AstraZeneca provided an update on the rapid development of its oncology pipeline at a briefing for analysts and investors...
New data show Giotrif® (afatinib) provided more than one year additional survival for lung cancer patients with the most common type of EGFR mutation (del19) compared to chemotherapy
3 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced results of the pre-specified individual, as well as the exploratory combined, analyses of two Phase III trials (LUX-Lung 3 and LUX-Lung 6)...
One- & two-year survival rates of 94% and 88% announced from Phase 1b trial of investigational PD-1 checkpoint inhibitor nivolumab and yervoy® (ipilimumab) in advanced melanoma
3 June 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced follow up results from Study -004, a multi-arm Phase 1b dose-ranging trial evaluating the safety and activity of the combination regimen of nivolumab...
Centre for Chemical Biology & Therapeutics at inStem licenses Cresset’s computational tools for lead optimization and identification
2 June 2014 | By kdm communications
Cresset is pleased to announce that the Centre for Chemical Biology and Therapeutics at The Institute for Stem Cell Biology and Regenerative Medicine (inStem), a state-of-the-art research institute in Bangalore, India...
Roche acquires Genia Technologies to strengthen next generation sequencing pipeline
2 June 2014 | By Roche
Roche announced the acquisition of Genia Technologies, Inc. (Genia), a privately held company, based in Mountain View, California, USA...
Novartis announces the appointment of Bruno Strigini as President of Novartis Oncology
2 June 2014 | By Novartis
Novartis announced the appointment of Bruno Strigini, as President of Novartis Oncology...
GSK announces Phase III ALTTO results for anti-HER2 therapy combination in the adjuvant breast cancer treatment setting
2 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the Phase III study of two anti-HER2 agents, lapatinib (Tykerb™/Tyverb™) and trastuzumab, did not meet the primary endpoint of improved disease free survival...
AstraZeneca welcomes positive data on the combination of olaparib and cediranib for the treatment of ovarian cancer patients
2 June 2014 | By AstraZeneca
As part of the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), Dr Joyce Liu presented data on a Phase II study conducted by the American National Cancer Institute...
New detailed Phase 3 data show Amgen’s novel investigational cholesterol-lowering medication evolocumab significantly reduced LDL Cholesterol
2 June 2014 | By Amgen
...in patients with a rare and serious genetic disorder that causes high cholesterol.
Avacta Analytical sponsors 5th Annual Protein Formulation Development and Drug Delivery Forum
2 June 2014 | By kdm communications
Avacta Analytical is pleased to announce its sponsorship of this year’s Protein Formulation Development and Drug Delivery Forum in Barcelona, Spain...
CHMP adopts positive opinion for plegridytm (peginterferon beta-1a) as a treatment for multiple sclerosis in the European Union
30 May 2014 | By Biogen Idec
Biogen Idec received a positive recommendation from the Committee for Medicinal Products for Human Use of the European Medicines Agency for the marketing authorisation of PLEGRIDY...
Data from Biogen Idec’s portfolio of multiple sclerosis therapies and pipeline featured at medical congresses
30 May 2014 | By Biogen Idec
Biogen Idec announced that more than 60 company-sponsored presentations highlighting key data from its industry-leading portfolio of marketed and investigational multiple sclerosis therapies are being featured during two neurology conferences...
